As of November 6, 2026, 4 holders' latest Schedule 13D or 13G filings report owning 5% or more of Aprea Therapeutics, Inc. The largest reported stake is Soleus Private Equity Fund III, L.P.'s, at 9.99%. 10 filings are on record since August 13, 2025 (Schedule 13G, April 1, 2026).
Sell to companies like Aprea Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Lytton Laurence W · Sole voting: 322,220 · Shared voting: 68,587 · Sole dispositive: 322,220 · Shared dispositive: 68,587 · SCHEDULE 13G/A, 2026-08-13
- · Holder: Vestal Point Capital, LP · Percent: 9.9% · SCHEDULE 13G
- · Holder: Orin Hirschman · Percent: 9.9% · SCHEDULE 13G/A
- · Holder: Squadron Master Fund LP · Percent: 9.9% · SCHEDULE 13G
- · Holder: Soleus Private Equity Fund III, L.P. · Percent: 9.99% · Shares: 1,271,080 · SCHEDULE 13G
Aprea Therapeutics, Inc. has 10 Schedule 13D or 13G filings on record since 2025-08-13. 4 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Soleus Private Equity Fund III, L.P. | 9.99% | 1,271,080 | SCHEDULE 13G, 2026-04-01 | 2026-04-01 |
| 9.9% | 1,186,294 | SCHEDULE 13G/A, 2026-04-27 | 2026-03-31 | |
| Squadron Master Fund LP | 9.9% | 1,271,081 | SCHEDULE 13G, 2026-04-07 | 2026-03-30 |
| Vestal Point Capital, LP | 9.9% | 22,654,832 | SCHEDULE 13G, 2026-05-15 | 2026-03-31 |
| Nantahala Capital Management, LLC | 4.5% | 411,520 | SCHEDULE 13G/A, 2026-02-13 | 2025-12-31 |
| 3.2% | 390,807 | SCHEDULE 13G/A, 2026-08-13 | 2026-06-30 | |
| Sio Capital Management, LLC | 1.93% | 112,223 | SCHEDULE 13G/A, 2025-11-12 | 2025-09-30 |
Holding shares or following this stake? See who's behind Aprea Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Aprea Therapeutics, Inc. and the records around it.
Aprea Therapeutics, Inc. elsewhere on the record
- Form D filing Dec 2025
- Who owns it
Companies that share a holder
- Soleus Private Equity Fund III, L.P. also filed stake reports on 5 other companies: Prelude Therapeutics Inc (Jul 2026), CALCIMEDICA, INC. (May 2026), INVIVYD, INC. (Feb 2026)
- Sio Capital Management, LLC also filed stake reports on 9 other companies: Enveric Biosciences, Inc. (Nov 2026), Adagio Medical Holdings, Inc. (Jul 2026), PMV Pharmaceuticals, Inc. (Jul 2026)
- Squadron Master Fund LP also filed stake reports on 14 other companies: Contineum Therapeutics, Inc. (Oct 2026), TCGX Acquisition Corp. II (Oct 2026), C4 Therapeutics, Inc. (Aug 2026)
Watch Aprea Therapeutics, Inc.
Get an email when Aprea Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Aprea Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Aprea Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Aprea Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
11 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Lytton Laurence W | 322,220 | 68,587 | 322,220 | 68,587 | SCHEDULE 13G/A, 2026-08-13 |
The latest filing identifies Aprea Therapeutics, Inc. by CUSIP 03836J201 and gives its principal executive office as 3805 OLD EASTON ROAD, DOYLESTOWN, PA 18902 (SCHEDULE 13G/A, 2026-08-13).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-13 | Sio Capital Management, LLC | 5.05% | SCHEDULE 13G/A |
| 2025-11-12 | Sio Capital Management, LLC | 1.93% | SCHEDULE 13G/A |
| 2025-11-17 | Lytton Laurence W | 9.9% | SCHEDULE 13G |
| 2026-01-28 | Orin Hirschman | 9.9% | SCHEDULE 13G/A |
| 2026-02-13 | Nantahala Capital Management, LLC | 4.5% | SCHEDULE 13G/A |
| 2026-04-01 | Soleus Private Equity Fund III, L.P. | 9.99% | SCHEDULE 13G |
| 2026-04-07 | Squadron Master Fund LP | 9.9% | SCHEDULE 13G |
| 2026-04-27 | Orin Hirschman | 9.9% | SCHEDULE 13G/A |
| 2026-05-15 | Vestal Point Capital, LP | 9.9% | SCHEDULE 13G |
| 2026-08-13 | Lytton Laurence W | 3.2% | SCHEDULE 13G/A |
Questions about who owns Aprea Therapeutics, Inc.
Who owns Aprea Therapeutics, Inc.?
On this page, 4 holders' latest ownership filings report 5% or more of Aprea Therapeutics, Inc.: Soleus Private Equity Fund III, L.P. (9.99%, Schedule 13G, filed 2026-04-01), Orin Hirschman (9.9%, Schedule 13G/A, filed 2026-04-27), Squadron Master Fund LP (9.9%, Schedule 13G, filed 2026-04-07) and Vestal Point Capital, LP (9.9%, Schedule 13G, filed 2026-05-15).
Who are the largest shareholders of Aprea Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Aprea Therapeutics, Inc. on this page are Soleus Private Equity Fund III, L.P. (9.99%), Orin Hirschman (9.9%) and Squadron Master Fund LP (9.9%).
When did Soleus Private Equity Fund III, L.P. buy into Aprea Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Soleus Private Equity Fund III, L.P. on this page is the Schedule 13G, filed 2026-04-01, reporting 9.99%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 10 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Aprea Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| December 29, 2025 | Form D, private offering | $3.06M sold | Form D page | Source |
Tools for this story
Each opens in a new tab, filled in for Aprea Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.